Sex Differences in Postoperative Recovery and Mortality After High-Risk Cardiac Surgery: A Propensity Score-Matched Post Hoc Analysis of the SUSTAIN-CSX Trial.

J Am Heart AssocAug 20, 2026 (epub)
Clinical ResearchCardiology

Rashad Zayat, Alish Kolashov, Christian Stoppe et al.

✦ AI-curated · Sources linked

In 30 seconds

This post hoc analysis of the SUSTAIN-CSX trial evaluated sex differences in postoperative recovery and mortality among high-risk cardiac surgery patients. In a matched cohort of 327 women and men, 180-day survival rates were similar, but women experienced longer intensive care unit stays (adjusted IRR, 1.8) and hospital stays (adjusted IRR, 1.4).

Key findings

  • 180-day survival did not differ significantly between women and men (log-rank P =0.086).
  • Women had a longer ICU stay with an adjusted incidence rate ratio of 1.8 (P =0.009).
  • Women also had a longer hospital stay with an adjusted incidence rate ratio of 1.4 (P =0.031).
  • Major postoperative complications were similar between sexes.

Why it matters

Understanding sex differences in postoperative recovery can inform clinical practices and resource allocation in cardiac surgery, potentially improving outcomes for female patients who may require longer recovery times.

Source

PubMed · PMID 42622119

Published in J Am Heart Assoc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.